{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:54:39Z","timestamp":1777395279032,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2021,4,20]]},"abstract":"<jats:p>Background: The PRESENILIN genes (PSEN1, PSEN2) encoding for their respective proteins have critical roles in many aspects of Alzheimer\u2019s disease (AD) pathogenesis. The PS2V transcript of PSEN2 encodes a truncated protein and is upregulated in AD brains; however, its relevance to AD and disease progression remains to be determined. Objective: Assess transcript levels in postmortem AD and non-AD brain tissue and in lymphocytes collected under the Australian Imaging Biomarker and Lifestyle (AIBL) study. Methods: Full length PSEN2 and PS2V transcript levels were assessed by quantitative digital PCR in postmortem brain tissue (frontal cortex and hippocampus) from control, AD, frontotemporal dementia (FTD), and Lewy body dementia (LBD). Transcript levels were also assessed in lymphocytes obtained from the Perth subset of the AIBL study (n\u200a=\u200a160). Linear regression analysis was used to assess correlations between transcript copy number and brain volume and neocortical amyloid load. Results: PS2V levels increased in AD postmortem brain but PS2V was also present at significant levels in FTD and LBD brains. PS2V transcript was detected in lymphocytes and PS2V\/PSEN2 ratios were increased in mild cognitive impairment (p\u200a=\u200a0.024) and AD (p\u200a=\u200a0.019) groups compared to control group. Increased ratios were significantly correlated with hippocampal volumes only (n\u200a=\u200a62, \u03b2=\u200a\u20130.269, p\u200a=\u200a0.03). Conclusion: Taken together, these results suggest that PS2V may be a marker of overall neurodegeneration.<\/jats:p>","DOI":"10.3233\/jad-201133","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T12:59:39Z","timestamp":1615294779000},"page":"1479-1489","source":"Crossref","is-referenced-by-count":5,"title":["Relevance of a Truncated PRESENILIN 2 Transcript to Alzheimer\u2019s Disease and Neurodegeneration"],"prefix":"10.1177","volume":"80","author":[{"given":"Seyyed Hani","family":"Moussavi Nik","sequence":"first","affiliation":[{"name":"University of Adelaide, School of Biological Sciences, Centre for Molecular Pathology, Adelaide, SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tenielle","family":"Porter","sequence":"additional","affiliation":[{"name":"Collaborative Genomics and Translation Group, Strategic Research Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia"},{"name":"School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Newman","sequence":"additional","affiliation":[{"name":"University of Adelaide, School of Biological Sciences, Centre for Molecular Pathology, Adelaide, SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Bartlett","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia"},{"name":"Department of Advanced Clinical and Translational Cardiovascular Imaging, Harry Perkins Institute of Medical Research, Murdoch, Western Australia, Australia"},{"name":"School of Medicine, University of Western Australia, Crawley, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Khan","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miheer","family":"Sabale","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia"},{"name":"Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Eccles","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Woodfield","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Groth","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Dore","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor L.","family":"Villemagne","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia"},{"name":"The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin L.","family":"Masters","sequence":"additional","affiliation":[{"name":"The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph N.","family":"Martins","sequence":"additional","affiliation":[{"name":"Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, New South Wales, Australia"},{"name":"School of Medical and Health Sciences, Edith Cowan University, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon M.","family":"Laws","sequence":"additional","affiliation":[{"name":"Collaborative Genomics and Translation Group, Strategic Research Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia"},{"name":"School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lardelli","sequence":"additional","affiliation":[{"name":"University of Adelaide, School of Biological Sciences, Centre for Molecular Pathology, Adelaide, SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Verdile","sequence":"additional","affiliation":[{"name":"Collaborative Genomics and Translation Group, Strategic Research Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia"},{"name":"School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-201133_ref1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3233\/JAD-151186","article-title":"Evidence for and against a pathogenic role of reduced gamma-secretase activity in familial Alzheimer\u2019s disease","volume":"52","author":"Jayne","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-201133_ref2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: A prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-201133_ref3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(18)30028-0","article-title":"Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer\u2019s disease: A longitudinal study","volume":"17","author":"Gordon","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-201133_ref4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41593-018-0070-z","article-title":"Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals","volume":"21","author":"Jacobs","year":"2018","journal-title":"Nat Neurosci"},{"key":"10.3233\/JAD-201133_ref5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/nbdi.2001.0473","article-title":"A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch","volume":"9","author":"Amtul","year":"2002","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-201133_ref6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.20083","article-title":"A novel presenilin 1 mutation associated with Pick\u2019s disease but not beta-amyloid plaques","volume":"55","author":"Dermaut","year":"2004","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-201133_ref7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/1098-1004(200007)16:1<95::AID-HUMU28>3.0.CO;2-H","article-title":"A novel presenilin 1 missense mutation (L153V) segregating with early-onset autosomal dominant Alzheimer\u2019s disease","volume":"16","author":"Raux","year":"2000","journal-title":"Hum Mutat"},{"key":"10.3233\/JAD-201133_ref8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3233\/JAD-2009-0986","article-title":"A novel Italian presenilin 2 gene mutation with prevalent behavioral phenotype","volume":"16","author":"Marcon","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-201133_ref9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/00001756-200205070-00036","article-title":"Alternative transcripts of presenilin-1 associated with frontotemporal dementia","volume":"13","author":"Evin","year":"2002","journal-title":"Neuroreport"},{"key":"10.3233\/JAD-201133_ref10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/13383","article-title":"Alzheimer disease PS-1 exon 9 deletion defined","volume":"5","author":"Prihar","year":"1999","journal-title":"Nat Med"},{"key":"10.3233\/JAD-201133_ref11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.ejhg.5200423","article-title":"Identification of a novel 4.6-kb genomic deletion in presenilin-1 gene which results in exclusion of exon 9 in a Finnish early onset Alzheimer\u2019s disease family: An Alu core sequence-stimulated recombination?","volume":"8","author":"Hiltunen","year":"2000","journal-title":"Eur J Hum Genet"},{"key":"10.3233\/JAD-201133_ref12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00001756-199512000-00071","article-title":"A mutation in Alzheimer\u2019s disease destroying a splice acceptor site in the presenilin-1 gene","volume":"7","author":"Perez-Tur","year":"1995","journal-title":"Neuroreport"},{"key":"10.3233\/JAD-201133_ref13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1006\/geno.1996.4523","article-title":"Analysis of the 5\u2019 sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset Alzheimer disease","volume":"40","author":"Rogaev","year":"1997","journal-title":"Genomics"},{"key":"10.3233\/JAD-201133_ref14","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1074\/jbc.M211827200","article-title":"Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer\u2019s disease with non-cored plaques and no neuritic dystrophy","volume":"278","author":"Kwok","year":"2003","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-201133_ref15","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1097\/00001756-199607080-00031","article-title":"Structure and alternative splicing of the presenilin-2 gene","volume":"7","author":"Prihar","year":"1996","journal-title":"Neuroreport"},{"key":"10.3233\/JAD-201133_ref16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1023\/A:1025537021543","article-title":"Two novel spliced presenilin 2 transcripts in human lymphocyte with oxidant stress and brain","volume":"252","author":"Takahashi","year":"2003","journal-title":"Mol Cell Biochem"},{"key":"10.3233\/JAD-201133_ref17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.molbrainres.2004.05.019","article-title":"Expression of truncated presenilin 2 splice variant in Alzheimer\u2019s disease, bipolar disorder, and schizophrenia brain cortex","volume":"127","author":"Smith","year":"2004","journal-title":"Brain Res Mol Brain Res"},{"key":"10.3233\/JAD-201133_ref18","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1074\/jbc.M006886200","article-title":"Increased production of beta-amyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin 2","volume":"276","author":"Sato","year":"2001","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-201133_ref19","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/acn3.755","article-title":"Alternative splicing in a presenilin 2 variant associated with Alzheimer disease","volume":"6","author":"Braggin","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.3233\/JAD-201133_ref20","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/sj.cdd.4401221","article-title":"Induced HMGA1a expression causes aberrant splicing of Presenilin-2 pre-mRNA in sporadic Alzheimer\u2019s disease","volume":"10","author":"Manabe","year":"2003","journal-title":"Cell Death Differ"},{"key":"10.3233\/JAD-201133_ref21","doi-asserted-by":"crossref","first-page":"e66235","DOI":"10.1371\/journal.pone.0066235","article-title":"The guinea pig as a model for sporadic Alzheimer\u2019s disease (AD): The impact of cholesterol intake on expression of AD-related genes","volume":"8","author":"Sharman","year":"2013","journal-title":"PLoS One"},{"key":"10.3233\/JAD-201133_ref22","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/brain\/awq033","article-title":"Alzheimer\u2019s disease phenotypes and genotypes associated with mutations in presenilin 2","volume":"133","author":"Jayadev","year":"2010","journal-title":"Brain"},{"key":"10.3233\/JAD-201133_ref23","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1093\/hmg\/ddv110","article-title":"Alzheimer\u2019s disease-related peptide PS2V plays ancient, conserved roles in suppression of the unfolded protein response under hypoxia and stimulation of gamma-secretase activity","volume":"24","author":"Moussavi Nik","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JAD-201133_ref24","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1046\/j.1471-4159.1999.0722498.x","article-title":"A novel presenilin-2 splice variant in human Alzheimer\u2019s disease brain tissue","volume":"72","author":"Sato","year":"1999","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-201133_ref25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1017\/S1041610209009405","article-title":"The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer\u2019s disease","volume":"21","author":"Ellis","year":"2009","journal-title":"Int Psychogeriatr"},{"key":"10.3233\/JAD-201133_ref26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nmeth.2027","article-title":"Digital PCR hits its stride","volume":"9","author":"Baker","year":"2012","journal-title":"Nat Methods"},{"key":"10.3233\/JAD-201133_ref27","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1016\/0022-1759(82)90269-1","article-title":"The evaluation of limiting dilution assays","volume":"49","author":"Fazekas de St","year":"1982","journal-title":"J Immunol Methods"},{"key":"10.3233\/JAD-201133_ref28","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1373\/clinchem.2013.214742","article-title":"Digital PCR as a novel technology and its potential implications for molecular diagnostics","volume":"59","author":"Huggett","year":"2013","journal-title":"Clin Chem"},{"key":"10.3233\/JAD-201133_ref29","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3233\/JAD-180713","article-title":"Utility of an Alzheimer\u2019s disease risk-weighted polygenic risk score for predicting rates of cognitive decline in preclinical Alzheimer\u2019s disease: A prospective longitudinal study","volume":"66","author":"Porter","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-201133_ref30","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","article-title":"Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-201133_ref31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"key":"10.3233\/JAD-201133_ref32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.22068","article-title":"18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial","volume":"68","author":"Vandenberghe","year":"2010","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"10.3233\/JAD-201133_ref33","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1016\/j.neurobiolaging.2014.04.033","article-title":"Comparison of MR-less PiB SUVR quantification methods","volume":"36","author":"Bourgeat","year":"2015","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-201133_ref34","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamaneurol.2013.1062","article-title":"Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease","volume":"70","author":"Dore","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-201133_ref35","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1046\/j.1365-2990.1999.00209.x","article-title":"Constitutive and cytokine-regulated expression of presenilin-1 and presenilin-2 genes in human neural cell lines","volume":"25","author":"Satoh","year":"1999","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.3233\/JAD-201133_ref36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00001756-200101220-00019","article-title":"Presenilin-2 (PS2) expression up-regulation in a model of retinopathy of prematurity and pathoangiogenesis","volume":"12","author":"Lukiw","year":"2001","journal-title":"Neuroreport"},{"key":"10.3233\/JAD-201133_ref37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-0115(02)00225-2","article-title":"Presenilins in the heart: Presenilin-2 expression is increased by low glucose and by hypoxia in cardiac cells","volume":"110","author":"Mohuczy","year":"2002","journal-title":"Regul Pept"},{"key":"10.3233\/JAD-201133_ref38","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1038\/tp.2011.55","article-title":"Metabolome in progression to Alzheimer\u2019s disease","volume":"1","author":"Oresic","year":"2011","journal-title":"Transl Psychiatry"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-201133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:05:21Z","timestamp":1777370721000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-201133"}},"subtitle":[],"editor":[{"given":"D. Allan","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":38,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jad-201133","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]}}}